drugset / Trial / NCT04363359
Clinical Trial of Quadrivalent Influenza Virus Split Vaccine
RandomizedParallel-groupDouble-blindPrevention
Summary
To evaluate the immunogenicity and safety of 2 doses of quadrivalent influenza virus split vaccine in healthy population aged 6-35 month., so as to provide a data support for phase III clinical trials.
Timeline
- Start
- 2020-01-15
- Primary completion
- 2021-09-14
- Completion
- 2021-09-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quadrivalent influenza vaccine | Vaccine | 0.25 ml | — |
| Subject | Quadrivalent influenza vaccine | Vaccine | 0.5 ml | — |
| Comparator | Trivalent influenza vaccine(B/V) | Vaccine | 0.25 ml | — |
| Comparator | Trivalent influenza vaccine(B/Y) | Vaccine | 0.25 ml | — |